Oxford Nanopore’s successful IPO is inspiring news for biotech entrepreneurs and a testament to the extraordinary vision of its founder and CEO Gordon Sanghera.

We invested in the DNA-sequencing company last year, and what a year it’s been! Now one of the UK’s most valuable startups, Oxford Nanopore has showed the world the value of its technology as researchers used it to characterise the Covid-19 genome and track new variants.

If you want to find out how Oxford Nanopore’s electronics-based sequencers increase the accuracy and richness of genetic data and drive down costs, leading to better research and facilitating machine learning, read Amadeus partner Andrea Traversone’s insightful blog here.